ARWR ARROWHEAD PHARMACEUTICALS, INC.companySEC Filings & Insider Trading Activity 2026
Latest ARROWHEAD PHARMACEUTICALS, INC. (ARWR) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on November 25, 2025, a 10-Q quarterly report filed on February 5, 2026, an 8-K current report filed on March 20, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for ARROWHEAD PHARMACEUTICALS, INC. (ARWR) (SEC CIK 879407), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 10-K Annual Report AnalysisLatest 10-K (2025-09-30)
Business Overview
- • Core business: RNA interference (RNAi) therapeutics silencing disease-causing genes via proprietary TRiM delivery platform
- • New commercial product: REDEMPLO® (plozasiran) FDA approved in 2025 for Familial Chylomicronemia Syndrome (FCS)
Risk Factors
- • Regulatory risk from FDA clinical trial authorizations for ARO-DM1 affecting milestone payments ($100M milestone triggered Nov 2025)
- • Geopolitical risk limited; primary macro exposure through $500M upfront from Sarepta and $200M from Novartis licensing agreements in FY 2025
Management Discussion & Analysis
- • Cash, cash equivalents, short-term investments sufficient for near-term needs as of Sept 30, 2025
- • Capital expenditures $12.5M in 2025, $136.9M in 2024 for manufacturing facility build-out; $0.1M more expected
AI 10-Q Quarterly Report AnalysisLatest 10-Q (2025-12-31)
Management Discussion & Analysis
- • Revenue $264.0M for Q1 FY2026, up $261.5M YoY from $2.5M in Q1 FY2025, driven by Sarepta, Novartis, Sanofi license agreements
- • Operating income $40.8M vs operating loss $(161.4)M YoY; net income $30.8M vs net loss $(173.1)M YoY; net income per diluted share $0.22 vs $(1.39)
Risk Factors
- • No new risk factors added this quarter compared to fiscal 2025 10-K
- • Most material risks remain consistent with those in fiscal 2025 10-K filing
Annual Reports Archive10-K
AI-powered analysis of ARROWHEAD PHARMACEUTICALS, INC. (ARWR) 10-K annual reports filed with SEC EDGAR.
Quarterly Reports Archive10-Q
AI-powered analysis of ARROWHEAD PHARMACEUTICALS, INC. (ARWR) 10-Q quarterly reports filed with SEC EDGAR.
Financial SummaryXBRL
| FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Revenue | $243.2M | $240.7M | $3.6M | $829.4M |
| Operating Income | -$178.5M | -$205.0M | -$601.1M | $98.3M |
| Net Income | -$176.1M | -$205.3M | -$599.5M | -$1.6M |
| Op. Margin | -73.4% | -85.2% | -16927.1% | 11.9% |
| Net Margin | -72.4% | -85.3% | -16882.4% | -0.2% |
| Balance Sheet | ||||
| Total Assets | $691.9M | $765.6M | $1.1B | $1.4B |
| Equity | $398.5M | $271.3M | $185.4M | $466.1M |
| ROE | -44.2% | -75.7% | -323.3% | -0.3% |
Source: XBRL financial data from ARROWHEAD PHARMACEUTICALS, INC. (ARWR) 10-K filings on SEC EDGAR. All figures in USD. Key metrics include revenue, net income, gross profit, gross profit margin, operating income, EPS (diluted), total assets, stockholders' equity, return on equity (ROE), operating cash flow, and capital expenditure.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Mar 20, 2026 | — | — | — |
10-Q | Feb 5, 2026 | Dec 31, 2025 | Analysis | |
8-K | Feb 5, 2026 | — | — | |
8-K | Jan 12, 2026 | — | — | |
8-K | Jan 9, 2026 | — | — | |
8-K | Jan 6, 2026 | — | — | |
10-K | Nov 25, 2025 | Sep 30, 2025 | Analysis | |
8-K | Nov 25, 2025 | — | — | |
10-Q | Aug 7, 2025 | Jun 30, 2025 | — | |
10-Q | May 12, 2025 | Mar 31, 2025 | — | |
10-Q | Feb 10, 2025 | Dec 31, 2024 | — | |
10-K | Nov 26, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 8, 2024 | Jun 30, 2024 | — | |
10-Q | May 9, 2024 | Mar 31, 2024 | — | |
10-Q | Feb 6, 2024 | Dec 31, 2023 | — | |
10-K | Nov 29, 2023 | Sep 30, 2023 | — | |
10-Q | Aug 7, 2023 | Jun 30, 2023 | — | |
10-Q | May 2, 2023 | Mar 31, 2023 | — | |
10-Q | Feb 6, 2023 | Dec 31, 2022 | — | |
10-K | Nov 28, 2022 | Sep 30, 2022 | — | |
10-Q | Aug 4, 2022 | Jun 30, 2022 | — | |
10-Q | May 10, 2022 | Mar 31, 2022 | — | |
10-Q | Feb 2, 2022 | Dec 31, 2021 | — | |
10-K | Nov 22, 2021 | Sep 30, 2021 | — | |
10-Q | Aug 5, 2021 | Jun 30, 2021 | — |
Frequently Asked Questions
What are the latest ARWR SEC filings in 2026?
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) has filed a 10-K annual report on November 25, 2025, a 10-Q quarterly report on February 5, 2026, an 8-K current report on March 20, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did ARWR file its most recent 10-K annual report?
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) filed its most recent 10-K annual report on November 25, 2025. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view ARWR 10-Q quarterly reports?
ARROWHEAD PHARMACEUTICALS, INC. (ARWR)'s most recent 10-Q quarterly report was filed on February 5, 2026. SignalX displays every ARWR 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has ARWR filed recently?
ARROWHEAD PHARMACEUTICALS, INC. (ARWR)'s most recent 8-K was filed on March 20, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find ARWR insider trading activity (Form 4)?
SignalX aggregates every ARWR Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does ARWR file with the SEC?
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new ARWR filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for ARROWHEAD PHARMACEUTICALS, INC. (ARWR).
What is ARWR's SEC CIK number?
ARROWHEAD PHARMACEUTICALS, INC. (ARWR)'s SEC CIK (Central Index Key) number is 879407. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 879407 to look up all ARWR filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find ARWR return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from ARROWHEAD PHARMACEUTICALS, INC. (ARWR) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of ARROWHEAD PHARMACEUTICALS, INC. SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 72+ filings.